No immediate trading implications. Monitor for subsequent Form 4 filings that may disclose actual stock transactions. The name change in 2025 and current insider reporting suggest ongoing corporate development, but no material financial or operational information is provided here.
Price Chart
Executive Summary
Daniel Faga, President and CEO of First Tracks Biotherapeutics, Inc., filed a Form 3 to report his initial beneficial ownership of securities in the company. This is a routine regulatory filing required when an officer becomes subject to insider reporting obligations, typically following a company name change or initial public offering.
Key Facts
- Daniel Faga filed Form 3 as President and CEO of First Tracks Biotherapeutics, Inc. (TRAX)
- Filing date: April 1, 2026
- This is an initial ownership report, indicating Faga has recently taken on an executive role requiring SEC reporting
- Company formerly known as Biopharma Company, Inc., changed name on October 10, 2025
Financial Impact
No financial impact disclosed — Form 3 does not report transaction values or share quantities in this filing
Risk Factors
- Lack of disclosed ownership amounts limits insight into insider stake size
- No financial data or forward-looking statements included in this filing
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001673528-26-000009 |
| Document: 0001673528-26-000009-index.html | 0001673528-26-000009 |
| Document: 0001673528-26-000009.txt | 0001673528-26-000009 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $43.80 | awaiting T+1 | — | $44.05 (+0.57%) |
Oct 20, 2026 5d ago | 8-K | $42.77 $43.14 | ▲ +0.87% | ▲ +2.05% | $44.05 (+2.99%) |
Oct 15, 2026 10d ago | 8-K | $34.46 $36.28 | ▼ −5.28% | ▼ −4.86% | $44.05 (−27.83%) |
Oct 15, 2026 11d ago | Press Release | $36.04 $34.46 | ▲ +4.38% | ▲ +3.28% | $44.05 (−22.23%) |
Oct 13, 2026 13d ago | 8-K | $31.68 $34.13 | ▲ +7.73% | ▲ +8.81% | $44.05 (+39.05%) |
Aug 12, 2026 10w ago | 8-K | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 12, 2026 10w ago | Press Release | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 7, 2026 11w ago | 3/A | $47.92 $46.75 | ▼ −2.44% | ▼ −2.12% | $44.05 (−8.08%) |
Jun 22, 2026 17w ago | 8-K | $17.78 $16.69 | ▼ −6.13% | ▼ −6.08% | $44.05 (+147.75%) |
May 14, 2026 23w ago | 8-K | $16.90 $17.79 | ▲ +5.27% | ▲ +5.33% | $44.05 (+160.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers